...
首页> 外文期刊>Modern Pathology >Primary Seminal Vesicle Carcinoma: An Immunohistochemical Analysis of Four Cases
【24h】

Primary Seminal Vesicle Carcinoma: An Immunohistochemical Analysis of Four Cases

机译:原发性精囊泡癌:4例免疫组织化学分析

获取原文
           

摘要

Primary adenocarcinoma of the seminal vesicles is an extremely rare neoplasm. Because prompt diagnosis and treatment are associated with improved long-term survival, accurate recognition of this neoplasm is important, particularly when evaluating limited biopsy material. Immunohistochemistry can be used to rule out neoplasms that commonly invade the seminal vesicles, such as prostatic adenocarcinoma. Previous reports have shown that seminal vesicle adenocarcinoma (SVCA) is negative for prostate-specific antigen (PSA) and prostate-specific acid phosphatase (PAP); however, little else is known of its immunophenotype. Consequently, we evaluated the utility of cancer antigen 125 (CA-125) and cytokeratin (CK) subsets 7 and 20 for distinguishing SVCA from other neoplasms that enter the differential diagnosis.Four cases of SVCA—three cases of bladder adenocarcinoma and a rare case of adenocarcinoma arising in a mullerian duct cyst—were immunostained for CA-125, CK7, and CK20. Three of four cases of SVCA were CA-125 positive and CK7 positive. All four cases were CK20 negative. All bladder adenocarcinomas and the mullerian duct cyst adenocarcinoma were CK7 positive and negative for CA-125 and CK20. In addition, CA-125 immunostaining was performed in neoplasms that commonly invade the seminal vesicles, including prostatic adenocarcinoma (n = 40), bladder transitional cell carcinoma (n = 32), and rectal adenocarcinoma (n = 10), and all were negative for this antigen.In conclusion, the present study has shown that the CK7-positive, CK20-negative, CA-125–positive, PSA/PAP-negative immunophenotype of papillary SVCA is unique and can be used in conjunction with histomorphology to distinguish it from other tumors that enter the differential diagnosis, including prostatic adenocarcinoma (CA-125 negative, PSA/PAP positive), bladder transitional cell carcinoma (CK20 positive, CA-125 negative), rectal adenocarcinoma (CA-125 negative, CK7 negative, CK20 positive), bladder adenocarcinoma (CA-125 negative), and adenocarcinoma arising in a mullerian duct cyst (CA-125 negative).
机译:精囊原发性腺癌是极为罕见的肿瘤。由于迅速的诊断和治疗与长期生存的改善相关,因此准确识别这种肿瘤非常重要,尤其是在评估有限的活检材料时。免疫组织化学可用于排除通常侵入精囊的肿瘤,例如前列腺腺癌。先前的报告显示,精囊腺癌(SVCA)对前列腺特异性抗原(PSA)和前列腺特异性酸性磷酸酶(PAP)呈阴性;然而,对其免疫表型知之甚少。因此,我们评估了癌抗原125(CA-125)和细胞角蛋白(CK)子集7和20在区分SVCA和进入鉴别诊断的其他肿瘤中的效用。SVCA 4例,膀胱腺癌3例,少见对在输尿管导管囊肿中出现的腺癌标本进行了CA-125,CK7和CK20免疫染色。 SVCA 4例中的3例是CA-125阳性和CK7阳性。所有四例均为CK20阴性。所有膀胱腺癌和苗勒氏管囊肿腺癌的CA-125和CK20 CK7阳性和阴性。此外,CA-125免疫染色是在通常侵袭精囊的肿瘤中进行的,包括前列腺腺癌(n = 40),膀胱移行细胞癌(n = 32)和直肠腺癌(n = 10),并且均为阴性。总之,本研究表明乳头状SVCA的CK7阳性,CK20阴性,CA-125阳性,PSA / PAP阴性免疫表型是独特的,可与组织形态学结合使用来区分它来自其他进入鉴别诊断的肿瘤,包括前列腺腺癌(CA-125阴性,PSA / PAP阳性),膀胱移行细胞癌(CK20阳性,CA-125阴性),直肠腺癌(CA-125阴性,CK7阴性,CK20阳性),膀胱腺癌(CA-125阴性)和缪勒氏管囊肿引起的腺癌(CA-125阴性)。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号